Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-243
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
ABBV-243 is an investigational drug candidate under development by AbbVie, currently in Phase 1 clinical evaluation. The compound is being studied in a randomized, double-blind, placebo-controlled trial to assess its safety, tolerability, pharmacokinetics, and immunogenicity in healthy adult volunteers, including those of Asian descent. The study utilizes a single ascending dose (SAD) design, with the drug being administered via both intravenous infusion and subcutaneous injection. While the specific molecular target and intended clinical indications have not yet been disclosed, the assessment of immunogenicity and the routes of administration suggest the molecule is likely a biologic or monoclonal antibody.
- Other names
- integrin beta-7 antibody
02
Targets
α4β7 (Integrin alpha-4 beta-7 heterodimer)αEβ7 (Integrin alphaEbeta7)ITGB7 (Integrin beta-7)
Beyond the preview
Go deeper on ABBV-243.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-243.